Vyome Holdings, Inc. - Asset Resilience Ratio
Vyome Holdings, Inc. (HIND) has an Asset Resilience Ratio of 5.51% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vyome Holdings, Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2018)
This chart shows how Vyome Holdings, Inc.'s Asset Resilience Ratio has changed over time. See Vyome Holdings, Inc. shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vyome Holdings, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HIND market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.55 Million | 5.51% |
| Total Liquid Assets | $2.55 Million | 5.51% |
Asset Resilience Insights
- Limited Liquidity: Vyome Holdings, Inc. maintains only 5.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vyome Holdings, Inc. Industry Peers by Asset Resilience Ratio
Compare Vyome Holdings, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Vyome Holdings, Inc. (2006–2018)
The table below shows the annual Asset Resilience Ratio data for Vyome Holdings, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 5.51% | $2.55 Million | $46.27 Million | -20.75pp |
| 2017-12-31 | 26.26% | $23.29 Million | $88.70 Million | -9.25pp |
| 2016-12-31 | 35.51% | $2.50 Million | $7.04 Million | -43.68pp |
| 2015-12-31 | 79.18% | $9.18 Million | $11.59 Million | +76.09pp |
| 2011-12-31 | 3.09% | $1.01 Million | $32.49 Million | -15.43pp |
| 2008-12-31 | 18.53% | $5.24 Million | $28.28 Million | +4.48pp |
| 2007-12-31 | 14.05% | $8.30 Million | $59.05 Million | -33.63pp |
| 2006-12-31 | 47.68% | $17.20 Million | $36.06 Million | -- |
About Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.